EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma

Edoardo De Simoni, Francesco Spagnolo, Sara Gandini, Aurora Gaeta, Giulio Rizzetto, Elisa Molinelli, Oriana Simonetti, Annamaria Offidani, Paola Queirolo

Cancer Treatment Reviews · 2024

DOI: 10.1016/j.ctrv.2024.102788 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024. Verfasst von Edoardo De Simoni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy. Hauptthemen laut MEDLINE: Melanoma, Neoplasm, Residual, Circulating Tumor DNA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with resected non-metastatic melanoma, the liquid biopsy for the assessment of molecular residual disease (MRD) by circulating tumour DNA (ctDNA) represents a promising tool to stratify the risk and to monitor tumour evolution. However, its validation requires the demonstration of analytical validity, clinical validity and utility. Indeed, the development of sensitive and specific assays can optimize prognostication and eventually help clinicians to modulate adjuvant treatments, in order to improve clinical outcomes. Data about ctDNA-guided prognosis stratification is emerging, but clinical trials assessing ctDNA-guided therapeutic decisions are still ongoing. This review aims to depict the role of ctDNA-based MRD assessment in patients with non-metastatic melanoma and to provide a roadmap to face challenges for its introduction into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoplasm, ResidualCirculating Tumor DNAHumansBiomarkers, TumorPrognosisLiquid BiopsySkin Neoplasms

Stichwörter der Autor:innen

Adjuvant therapyCirculating tumour DNALiquid biopsyMolecular residual diseaseNon-metastatic melanoma

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
  • Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Surgical Sciences and Integrated Diagnostics (DISC), Plastic Surgery Division, University of Genova, Genova, Italy.
  • Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: paola.queirolo@ieo.it.

Zitieren

APA

De Simoni, E., Spagnolo, F., Gandini, S., Gaeta, A., Rizzetto, G., Molinelli, E., Simonetti, O., Offidani, A., & Queirolo, P. (2024). Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2024.102788

Vancouver

De Simoni E, Spagnolo F, Gandini S, Gaeta A, Rizzetto G, Molinelli E, et al. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma. Cancer Treatment Reviews. 2024. doi:10.1016/j.ctrv.2024.102788

BibTeX
@article{DeSimoni2024,
  author = {De Simoni, Edoardo and Spagnolo, Francesco and Gandini, Sara and Gaeta, Aurora and Rizzetto, Giulio and Molinelli, Elisa and Simonetti, Oriana and Offidani, Annamaria and Queirolo, Paola},
  title = {Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma},
  journal = {Cancer Treatment Reviews},
  year = {2024},
  doi = {10.1016/j.ctrv.2024.102788}
}
Kostenlos starten →